Vaccitech plc (VACC): Price and Financial Metrics
GET POWR RATINGS... FREE!
VACC Stock Summary
- VACC's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
- Of note is the ratio of VACCITECH PLC's sales and general administrative expense to its total operating expenses; merely 0.42% of US stocks have a lower such ratio.
- As for revenue growth, note that VACC's revenue has grown 14,170.52% over the past 12 months; that beats the revenue growth of 99.82% of US companies in our set.
- Stocks that are quantitatively similar to VACC, based on their financial statements, market capitalization, and price volatility, are BEAM, RPTX, KROS, LYRA, and INMB.
- VACC's SEC filings can be seen here. And to visit VACCITECH PLC's official web site, go to www.vaccitech.co.uk.
VACC Valuation Summary
- In comparison to the median Healthcare stock, VACC's price/earnings ratio is 60.79% lower, now standing at 8.9.
- Over the past 21 months, VACC's price/sales ratio has gone down 97.
Below are key valuation metrics over time for VACC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VACC | 2023-01-20 | 2.6 | 0.4 | 8.9 | -10.1 |
| VACC | 2023-01-19 | 2.6 | 0.4 | 8.9 | -10.1 |
| VACC | 2023-01-18 | 2.7 | 0.4 | 8.9 | -10.0 |
| VACC | 2023-01-17 | 2.7 | 0.4 | 9.0 | -9.9 |
| VACC | 2023-01-13 | 2.7 | 0.4 | 8.9 | -10.0 |
| VACC | 2023-01-12 | 2.7 | 0.4 | 8.9 | -10.0 |
VACC Stock Price Chart Interactive Chart >
VACC Price/Volume Stats
| Current price | $2.95 | 52-week high | $10.45 |
| Prev. close | $3.05 | 52-week low | $2.02 |
| Day low | $2.89 | Volume | 39,100 |
| Day high | $3.28 | Avg. volume | 42,228 |
| 50-day MA | $2.45 | Dividend yield | N/A |
| 200-day MA | $3.73 | Market Cap | 110.03M |
Vaccitech plc (VACC) Company Bio
Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.
Latest VACC News From Around the Web
Below are the latest news stories about VACCITECH PLC that investors may wish to consider to help them evaluate VACC as an investment opportunity.
Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune DiseasesOXFORD, United Kingdom, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced that it will host a Key Opinion Leader (KOL) webinar on its SNAPvax™ Platform and application in tolerogenic immunotherapies for celiac disease and other autoimmune diseases on Monday, November 28, 2022 at 4:30 pm ET. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infec |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're beginning the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday morning! |
Analysts Are Bullish on These Healthcare Stocks: RAPT Therapeutics (RAPT), Vaccitech Plc (VACC)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RAPT Therapeutics (RAPT – Research Report), Vaccitech Plc (VACC – Research Report) and LAVA Therapeutics (LVTX – Research Report) with bullish sentiments. RAPT Therapeutics (RAPT) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on RAPT Therapeutics today and set a price target of $50.00. The company's shares closed last Friday at $24.17. According to TipRanks. |
Vaccitech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagVaccitech ( NASDAQ:VACC ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.17m (up by US$6.15m from 3Q... |
Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsOXFORD, United Kingdom, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments. Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity, and cancer. “This has been a very exciting qua |
VACC Price Returns
| 1-mo | 39.80% |
| 3-mo | 7.27% |
| 6-mo | -39.18% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 25.53% |
| 2022 | -78.85% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...